News | July 09, 2009

Economy Forces European Institutions to Select Lower-Priced Interventional Cardiology Devices

July 9, 2009 – According to Millennium Research Group (MRG), the ongoing economic crisis is putting pressure on publicly funded European healthcare systems, intensifying the decline of interventional cardiology device prices in the region.

MRG's “European Markets for Interventional Cardiology Devices 2009 (Part II)” report details the extent to which competitive pricing and discounts among interventional cardiology device vendors is resulting in price erosion in Belgium, Luxembourg, the Netherlands, Norway, Denmark, Finland, Sweden, Spain and Switzerland.

IC device vendors are engaging in price undercutting and offering high-volume discounts or bundling deals with other products in their portfolios in order to encourage sales, resulting in price erosion. The healthcare systems in the Netherlands and Switzerland (beginning in 2012) provide only general funding for IC procedures, despite the varying cost of devices used. In order to operate within set budgets, European healthcare facilities must often choose lower-cost devices. Contract tenders between sellers and group purchasing organizations will further add to price erosion. In exchange for high-volume sales of their products, manufacturers offer significant discounts. This method of business is becoming more common across Europe, particularly in the Nordic countries and Spain.

MRG's new report provides important insight into the reasons behind and extent of the changes in interventional cardiology device pricing. Additionally, the report provides full breakdowns of procedures by type and device unit sales by subtype, including five-year forecasts, up-to-date market shares and in-depth qualitative insights.

For more information: www.MRG.net

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...